Additional evidence of distinct outcomes in human and mouse cells arise from the observation that there is a significant increase in RANKL promotor activation in murine bone marrow stromal cells after exposure to paracrine signaling from BC cells (Figure S7). This evidence concerns the gene TNFSF11 and breast cancer.